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Abstract
Background: Alzheimer’s disease (AD) and its transitional state mild cognitive impairment (MCI) are characterized by
amyloid plaque and tau neurofibrillary tangle (NFT) deposition within the cerebral neocortex and neuronal loss within the
hippocampal formation. However, the precise relationship between pathologic changes in neocortical regions and
hippocampal atrophy is largely unknown.
Methodology/Principal Findings: In this study, combining structural MRI scans and automated image analysis tools with
reduced cerebrospinal fluid (CSF) Aß levels, a surrogate for intra-cranial amyloid plaques and elevated CSF phosphorylated
tau (p-tau) levels, a surrogate for neocortical NFTs, we examined the relationship between the presence of Alzheimer’s
pathology, gray matter thickness of select neocortical regions, and hippocampal volume in cognitively normal older
participants and individuals with MCI and AD (n=724). Amongst all 3 groups, only select heteromodal cortical regions
significantly correlated with hippocampal volume. Amongst MCI and AD individuals, gray matter thickness of the entorhinal
cortex and inferior temporal gyrus significantly predicted longitudinal hippocampal volume loss in both amyloid positive
and p-tau positive individuals. Amongst cognitively normal older adults, thinning only within the medial portion of the
orbital frontal cortex significantly differentiated amyloid positive from amyloid negative individuals whereas thinning only
within the entorhinal cortex significantly discriminated p-tau positive from p-tau negative individuals.
Conclusions/Significance: Cortical Ab and tau pathology affects gray matter thinning within select neocortical regions and
potentially contributes to downstream hippocampal degeneration. Neocortical Alzheimer’s pathology is evident even
amongst older asymptomatic individuals suggesting the existence of a preclinical phase of dementia.
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Selective neurodegeneration of the cerebral cortex is a
characteristic pathological feature of Alzheimer’s disease (AD).
Intracellular tau-associated neurofibrillary tangles (NFTs) and
extracellular amyloid-ß (Aß) associated plaques show a character-
istic laminar and regional pattern of distribution within gray
matter, with greater involvement of the medial temporal lobe and
heteromodal association areas than primary sensory or motor
cortices [1–3]. Within heteromodal association cortices, long
corticocortical projections and the large pyramidal neurons in
layers III and V that give rise to these projections appear to be
especially vulnerable [4,5]. As such, it has been postulated that
early disruptions in heteromodal association cortices can contrib-
ute to a functional isolation of the hippocampal formation thus
giving rise to the clinical hallmark of Alzheimer’s disease,
progressive memory impairment [6,7].
Recent advances in neuroimaging and image analysis algo-
rithms allow for the in vivo assessment of neuropathologic changes
underlying AD. Positron emission tomography (PET) studies
examining fibrillar amyloid deposition with Pittsburgh Compound
B (PiB) and MRI studies of functional and structural connectivity
have observed a significant overlap in a number of neocortical
regions that appear preferentially affected in the earliest stages of
AD [8–14]. Taken collectively, these studies suggest that select
heteromodal cortical regions are vulnerable to amyloid deposition
and exhibit neuronal dysfunction early in the disease process. In
comparison, though several studies have demonstrated a relation-
ship between post-mortem NFT pathology and structural MRI
measures of atrophy [15,16], few have examined in vivo the effect
of tau burden on atrophy in heteromodal and limbic cortices.
Cortical atrophy resultingfrom cellular shrinkage, dendritic spine
loss, and axonal disruption is reflected as a loss of gray matter that
diminishes cortical thickness [17,18]. Prior MRI studies of AD have
shown cortical thinning and gray matter disturbances in medial
temporal [19–21], temporo-parietal [22–25], posterior cingulate
and medial frontal cortices [10,26]. Still, the precise relationship
between amyloid and tau pathology, regional neocortical thinning,
and hippocampal atrophy is largely unknown. In this study, using
significant reductions in cerebrospinal fluid (CSF) Aß levels as a
surrogate for elevated intra-cranial amyloid plaques [27,28] and
significant elevations in CSF phosphorylated tau levels as a
surrogate for neocortical NFTs [29], we explored relationships
between the presence of Alzheimer’s pathology, thickness of select
neocortical regions and the volume of the hippocampus.
Methods
Overview
All 724 participants were selected from the Alzheimer’s disease
Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/
ADNI). The ADNI is a large multi-site collaborative effort
launched in 2003 by the National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering, the Food and
Drug Administration, private pharmaceutical companies and non-
profit organizations as a public–private partnership aimed at
testing whether serial MRI, PET, other biological markers and
clinical and neuropsychological assessment can be combined to
measure the progression of MCI and early AD. The Principal
Investigator of this initiative is Michael Weiner, MD, and ADNI is
the result of many co-investigators from a broad range of academic
institutions and private corporations, with subjects recruited from
over 50 sites across the US and Canada. For more information,
please see http://www.adni-info.org.
Clinical Assessments and Group Characteristics
Each participant from the ADNI cohort was formally evaluated
using eligibility criteria that are described in detail elsewhere
(http://www.adni-info.org/index.php?option=com_content&task=
view&id=9&Itemid=43). The institutional review boards of all
participating institutions approved the procedures for this study.
Written informed consent was obtained from all participants or
surrogates. Briefly, experienced clinicians conducted independent
semi-structured interviews with the participant and a knowledgeable
collateral source that included a health history, neurological
examination, the Mini-Mental State Examination [30], the CDR-
Sum of Boxes [31], and a comprehensive neuropsychological battery.
As illustrated in Table 1, participants from the ADNI database
were selected if they were clinically classified as:
N CN (n=208) - Individuals who were cognitively normal at
baseline and clinical follow-up (CDR 0).
N MCI (n=353) – Individuals with mild cognitive impairment
(MCI) defined using the revised MCI criteria [32].
N AD (n=163) – Individuals who met criteria for probable AD
[33] (CDR 1).
MRI image acquisition
All ADNI MRI scans were acquired at multiple sites using
either a GE, Siemens, or Philips 1.5T system. Multiple high-
resolution T1- weighted volumetric MP-RAGE scans were
collected for each subject and the raw DICOM images were
downloaded from the public ADNI site (http://www.loni.ucla.
edu/ADNI/Data/index.shtml). Parameter values vary depending
on scanning site and can be found at http://www.loni.ucla.edu/
ADNI/Research/Cores/.
MRI Image Processing
All MRI scans were processed, with little to no manual
intervention using the FreeSurfer software package (version 4.5),
freely available at http://surfer.nmr.mgh.harvard.edu. A single
MPRAGE MRI acquisition for each participant was normalized
for intensity inhomogeneities to create an image volume with
high contrast-to-noise [34]. The intensity-normalized volume
was used to automatically locate the gray/white matter boundary
Table 1. Descriptive statistical information for the
participants in the study (means listed with standard
deviations in parentheses).
Diagnostic Group CN MCI AD
Sample Size 208 353 163
Age 76.0
(4.9)
74.5
(7.4)
74.9
(7.5)
Percent Female 48% 37% 50%
Education 16.1
(2.8)
15.7
(3.0)
14.8
(3.2)
Mini Mental State Examination 29.1
(1.0)
27.0
(1.8)
23.3
(1.9)
CDR-Sum of Boxes 0 1.6
(0.9)
4.2
(1.6)
APOE-e4 carrier status 27% 54% 66%
Mean Hippocampal Volume (head size
corrected)
5.0
(0.54)
4.41
(0.66)
4.07
(0.66)
doi:10.1371/journal.pone.0012853.t001
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(gray matter surface) [36]. Cortical thickness measurements were
then obtained by calculating the distance between these two
boundaries across the entire cortical mantle of each hemisphere
[36].
The neocortex of the brain on the MRI scans was then
automatically subdivided into gyral-based regions of interest
(ROIs). To accomplish this, a registration procedure was used
that aligns the cortical folding patterns [37] and probabilistically
assigns every point on the cortical surface to one of the 32 ROIs
[38]. For the purposes of this study, we focused on 8 ROIs
bilaterally corresponding to neocortical regions that prior
neuropathological [1–3], neuroimaging [19–26], and amyloid
[10,12] studies have demonstrated as being affected early in the
course of AD. These regions included the 1) caudal portion of the
middle frontal gyrus (includes inferior frontal sulcus), 2) medial
portion of the orbital frontal cortex, 3) inferior parietal lobule
(includes inferior parietal sulcus), 4) lateral portion of the occipital
cortex, 5) inferior temporal gyrus, 6) entorhinal cortex, 7) temporal
pole, and 8) isthmus portion of the cingulate cortex (includes
posterior cingulate and retrosplenial cortices) (Figure 1). The
hippocampus was automatically delineated based on an algorithm
that uses a probabilistic atlas and examines variations in voxel
intensities and spatial relationships to classify subcortical regions
on MRI scans [39].
For longitudinal analysis, the baseline and one-year follow-up
structural MRI scans were rigid body registered and an unbiased
template volume was created [40]. All time points and the
template images were then skull stripped, intensity normalized and
segmented independently. The longitudinal segmentation results
were then obtained by directly mapping the linear Talairach
transform and the brain mask from the template to the baseline
and follow-up timepoint, and by initializing other processing steps
such as the non-linear warps and intensity normalizations with the
results from the template. For the baseline and follow-up
timepoint, a fused segmentation image that incorporates informa-
tion of both time points was used as an initial estimate to guide the
final delineation of the hippocampus. Atrophy rate of the
hippocampus was defined as percent volume loss over the course
of one year. A more detailed description of these procedures can
be found in [40].
Cerebrospinal Fluid Measures
From the current ADNI sample, a number of individuals
(n=338) underwent lumbar puncture for CSF biomarker evalua-
tion. Methods for CSF acquisition and biomarker measurement
have been reported previously for this sample [28]. In brief, CSF
wascollectedandstoredat 280uC at the University ofPennsylvania
ADNI Biomarker Core Laboratory. Amyloid beta from peptides 1–
42 (Ab) and tau phosphorylated at threonine 181 (p-tau) was
measured using the multiplex xMAP Luminex platform (Luminex
Corp, Austin TX) with Innogenetics (INNOBIA AlzBio3, Ghent,
Belgium) immunoassay kit–based reagents. Using a previously
established CSF-based Ab cutoff value of 192 pg/ml and a p-tau
cutoffvalueof23 pg/ml[28],weclassifiedMCIand ADindividuals
as 1) amyloid positive (n=193, 43% female, mean age=74.0,
SD=7.4), 2) amyloid negative (n=48, 30% female, mean
age=75.9, SD=8.0), 3) p-tau positive (n=182, 44% female, mean
age=74.0, SD=7.5), and 4) p-tau negative (n=59, 30% female,
mean age=76.1, SD=7.6). Similarly, we additionally classified CN
individuals as a) amyloid positive (n=35, 54% female, mean
age=76.3, SD=5.1), b) amyloid negative (n=61, 50% female,
mean age=75.6, SD=5.3), c) p-tau positive (n=34, 47% female,
mean age=77.8, SD=5.9), and d) p-tau negative (n=62, 30%
female, mean age=74.7, SD=4.4). Of note, 46% (n=16) of the
amyloid positive individuals were additionally p-tau positive and
47% (n=16) of the p-tau positive individuals were additionally
amyloid positive.
Statistical Analysis
Spearman’s rank correlation coefficients were first used to
examine relationships between the mean thickness of the
Figure 1. Three-dimensional representations of the 8 ROIs examined in the current study (only right hemisphere is shown). All of the
ROIs visible in the lateral (top) and medial (bottom) views of the gray matter surface.
doi:10.1371/journal.pone.0012853.g001
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regression models were constructed for the amyloid positive,
amyloid negative, p-tau positive and p-tau negative MCI and AD
individuals, with the baseline thickness of the individual ROIs as
predictors for hippocampal atrophy rate. Logistic regression
models and multivariate analysis of variance (MANOVA) were
used to compare whether baseline thickness of the individual ROIs
significantly differentiated amyloid positive from amyloid negative
as well as p-tau positive from p-tau negative CN individuals. In all
of the analyses performed, age, gender, education, and APOE-e4
carrier status were additionally included.
Results
Correlations between regional neocortical thickness and
hippocampal volume
Overall, the hippocampus demonstrated the largest magnitude
of correlation with the entorhinal cortex (Spearman’s r=0.66,
p,0.001), temporal pole (Spearman’s r=0.51, p,0.001), inferior
temporal gyrus (Spearman’s r=0.45, p,0.001) and the medial
portion of the orbital frontal cortex (Spearman’s r=0.41,
p,0.001) (Table 2). The inferior parietal lobule and caudal
portion of the middle frontal gyrus showed the strongest
magnitude of correlation with each other and with the other
neocortical regions (Table 2). Within the AD cohort, the
hippocampus did not demonstrate any significant correlations
with any of the lateral frontal, occipital, or parietal regions
including the isthmus portion of the cingulate cortex (Spearman’s
r=0.12, p.0.05) but correlated significantly with the entorhinal
cortex (Spearman’s r=0.57, p,0.001), temporal pole (Spear-
man’s r=0.38, p,0.001), inferior temporal gyrus (Spearman’s
r=0.23, p,0.01), and the medial portion of the orbital frontal
cortex (Spearman’s r=0.33, p,0.001) (Table 3). In comparison,
within MCI cohort, the hippocampus correlated significantly with
each neocortical region (Table 4) and similarly, within the CN
cohort the hippocampus correlated significantly with all neocor-
tical regions except the lateral portion of the occipital cortex
(Spearman’s r=0.03, p.0.05) (Table 5).
Regional cortical thickness, Ab, and p-tau as predictors of
hippocampal atrophy
Linear regression models amongst the MCI and AD individuals
demonstrated that decreased Ab levels (ß-coefficient=20.08,
Table 2. Correlation results between cortical thickness of
eight neocortical ROIs and total hippocampal volume in all
ADNI participants (n=724).
Regions of
Interest HV CMF ERC IPL ITG ISC LOC MOF TP
HV 1 0.29 0.66 0.32 0.45 0.36 0.28 0.41 0.51
CMF 1 0.38 0.79 0.65 0.60 0.64 0.43 0.42
ERC 1 0.43 0.63 0.43 0.36 0.44 0.72
IPL 1 0.74 0.67 0.74 0.44 0.44
ITG 1 0.63 0.64 0.51 0.64
ISC 1 0.52 0.50 0.43
LOC 1 0.38 0.38
MOF 1 0.48
TP 1
Spearman’s rank correlation coefficients listed, all p-values significant at
,0.0001. All analyses included age, gender, education, and APOE-e4 carrier
status as co-variates. HV=Hippocampal volume, CMF=Caudal portion of
middle frontal gyrus thickness, ERC=Entorhinal cortex thickness, IPL=Inferior
parietal lobule thickness, ITG=Inferior temporal gyrus thickness, ISC=Isthmus
portion of cingulate cortex thickness, LOC=Lateral portion of occipital cortex
thickness, MOF=Medial portion of orbital frontal cortex thickness,
TP=Temporal pole thickness.
doi:10.1371/journal.pone.0012853.t002
Table 3. Correlation results between cortical thickness of eight neocortical ROIs and total hippocampal volume in only AD
individuals (n=163).
Regions of Interest HV CMF ERC IPL ITG ISC LOC MOF TP
HV 1 0.02
(NS)
0.57
(0.0001)
0.03
(NS)
0.23
(0.003)
0.12
(NS)
0.12
(NS)
0.33
(0.0001)
0.38
(0.0001)
CMF 1 0.17
(0.02)
0.77
(0.0001)
0.56
(0.0001)
0.58
(0.0001)
0.59
(0.0001)
0.27
(0.0005)
0.24
(0.002)
ERC 1 0.12
(NS)
0.49
(0.0001)
0.27
(0.007)
0.19
(0.01)
0.38
(0.0001)
0.67
(0.0001)
IPL 1 0.63
(0.0001)
0.64
(0.0001)
0.67
(0.0001)
0.24
(0.001)
0.23
(0.01)
ITG 1 0.58
(0.0001)
0.51
(0.0001)
0.46
(0.0001)
0.61
(0.0001)
ISC 1 0.49
(0.0001)
0.42
(0.0001)
0.34
(0.0001)
LOC 1 0.36
(0.0001)
0.29
(0.0001)
MOF 1 0.52
(0.0001)
TP 1
Spearman’s rank correlation coefficients listed with p-values in parentheses. All analyses included age, gender, education, and APOE-e4 carrier status as co-variates.
HV=Hippocampal volume, CMF=Caudal portion of middle frontal gyrus thickness, ERC=Entorhinal cortex thickness, IPL=Inferior parietal lobule thickness,
ITG=Inferior temporal gyrus thickness, ISC=Isthmus portion of cingulate cortex thickness, LOC=Lateral portion of occipital cortex thickness, MOF=Medial portion of
orbital frontal cortex thickness, TPC=Temporal pole thickness, NS=Not significant.
doi:10.1371/journal.pone.0012853.t003
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increased p-tau levels (ß-coefficient=0.02, 95% CI=0.006 to
0.03, p,0.01) significantly predicted hippocampal atrophy rate.
Within the amyloid positive MCI and AD individuals, baseline
thickness of the entorhinal cortex (ß-coefficient=20.79, 95%
CI=21.20 to 20.37, p,0.0001) and inferior temporal gyrus (ß-
coefficient=21.04, 95% CI=22.14 to 20.06, p,0.05) signifi-
cantly predicted the atrophy rate of the hippocampus. Similarly,
within the p-tau positive individuals, baseline thickness of the
entorhinal cortex (ß-coefficient=20.66, 95% CI=21.09 to
20.23, p,0.01) and inferior temporal gyrus (ß-coeffi-
cient=21.20, 95% CI=22.31 to 20.10, p,0.05) significantly
predicted the atrophy rate of the hippocampus (Figure 2). Within
the amyloid negative and p-tau negative MCI and AD individuals,
none of the neocortical regions significantly predicted longitudinal
hippocampal atrophy.
Regional cortical thinning in cognitively normal older
individuals
Logistic regression models amongst the CN cohort demonstrat-
ed that APOE-e4 carrier status (Odds Ratio (OR)=0.08, 95%
CI=0.02 to 0.27, p,0.0001) and thinning in the medial portion
of the orbital frontal cortex (OR=5.77, 95% CI=1.12 to 44.80,
p,0.05) significantly differentiated the amyloid positive from
amyloid negative older individuals whereas thinning of the
entorhinal cortex (OR=2.99, 95% CI=1.10 to 9.73, p,0.05)
significantly differentiated the p-tau positive from p-tau negative
older individuals (Figure 3). None of the other measures, including
baseline hippocampal volume, showed any significant effects. A
MANOVA confirmed that only APOE-e4 carrier status (F=18.5,
p,0.0001) and thinning of the medial orbital frontal cortex
significantly (F=3.73, p,0.05) differentiated amyloid positive
from amyloid negative individuals and only thinning of the
entorhinal cortex (F=3.58, p,0.05) significantly discriminated p-
tau positive from p-tau negative individuals.
Discussion
Our results demonstrate that 1) amongst cognitively normal
older participants and individuals with MCI and AD, select
heteromodal association cortices correlate with hippocampal
volume, 2) amongst MCI and AD individuals, gray matter
thinning within the same two neocortical regions predicts
Table 5. Correlation results between cortical thickness of eight neocortical ROIs and total hippocampal volume in only CN
individuals (n=208).
Regions of Interest HV CMF ERC IPL ITG ISC LOC MOF TP
HV 1 0.16
(0.02)
0.36
(0.0001)
0.15
(0.02)
0.20
(0.003)
0.19
(0.005)
0.03
(NS)
0.29
(0.0001)
0.23
(0.0005)
CMF 1 0.27
(0.0001)
0.76
(0.0001)
0.51
(0.0001)
0.49
(0.0001)
0.62
(0.0001)
0.34
(0.0005)
0.38
(0.002)
ERC 1 0.35
(0.0001)
0.52
(0.0001)
0.31
(0.007)
0.28
(0.0001)
0.37
(0.0001)
0.56
(0.0001)
IPL 1 0.63
(0.0001)
0.51
(0.0001)
0.75
(0.0001)
0.38
(0.001)
0.40
(0.01)
ITG 1 0.48
(0.0001)
0.57
(0.0001)
0.38
(0.0001)
0.49
(0.0001)
ISC 1 0.44
(0.0001)
0.38
(0.0001)
0.23
(0.0005)
LOC 1 0.31
(0.0001)
0.31
(0.0001)
MOF 1 0.35
(0.0001)
TP 1
Spearman’s rank correlation coefficients listed with p-values in parentheses. All analyses included age, gender, education, and APOE-e4 carrier status as co-variates.
HV=Hippocampal volume, CMF=Caudal portion of middle frontal gyrus thickness, ERC=Entorhinal cortex thickness, IPL=Inferior parietal lobule thickness,
ITG=Inferior temporal gyrus thickness, ISC=Isthmus portion of cingulate cortex thickness, LOC=Lateral portion of occipital cortex thickness, MOF=Medial portion of
orbital frontal cortex thickness, TPC=Temporal pole thickness, NS=Not significant.
doi:10.1371/journal.pone.0012853.t005
Table 4. Correlation results between cortical thickness of
eight neocortical ROIs and total hippocampal volume in only
MCI individuals (n=353).
Regions of
Interest HV CMF ERC IPL ITG ISC LOC MOF TP
HV 1 0.18 0.61 0.21 0.36 0.28 0.27 0.32 0.48
CMF 1 0.27 0.76 0.63 0.57 0.59 0.43 0.34
ERC 1 0.31 0.55 0.31 0.30 0.37 0.73
IPL 1 0.72 0.65 0.71 0.40 0.37
ITG 1 0.58 0.61 0.47 0.59
ISC 1 0.48 0.48 0.37
LOC 1 0.33 0.31
MOF 1 0.43
TP 1
Spearman’s rank correlation coefficients, all p-values significant at ,0.0001. All
analyses included age, gender, education, and APOE-e4 carrier status as co-
variates. HV=Hippocampal volume, CMF=Caudal portion of middle frontal
gyrus thickness, ERC=Entorhinal cortex thickness, IPL=Inferior parietal lobule
thickness, ITG=Inferior temporal gyrus thickness, ISC=Isthmus portion of
cingulate cortex thickness, LOC=Lateral portion of occipital cortex thickness,
MOF=Medial portion of orbital frontal cortex thickness, TPC=Temporal pole
thickness.
doi:10.1371/journal.pone.0012853.t004
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and p-tau positive individuals and 3) amongst cognitively normal
older adults, thinning within the medial portion of the orbital
frontal cortex significantly differentiates amyloid positive from
amyloid negative individuals whereas entorhinal cortex thinning
significantly discriminates p-tau positive from p-tau negative
individuals. Taken collectively, this indicates that cortical Ab
and tau pathology is evident even among asymptomatic older
individuals, affects gray matter thinning within select neocortical
regions and potentially contributes to downstream hippocampal
degeneration. These findings are in agreement with prior work
indicating the value of CSF Ab as an early biomarker [41] and
provide evidence that CSF p-tau and structural MRI measures are
additionally informative in the earliest phase of the disease process.
Relationship between thickness of heteromodal regions
and hippocampal volume
The four cerebral cortical regions that best correlated with
hippocampal volume follow an interesting neurodevelopmental
pattern. On architectonic grounds, the regions identified on the
lateral hemisphere trace evolutionary lineage from the so-called
‘paleocortical’ trend whereas regions identified on the medial
hemisphere are derived from the ‘archicortical’ trend [42–44]. As
first described by Kemper [3], these regions collectively subserve
the ‘special senses of the head’ including vision, memory, emotion,
olfaction, and audition and are inherently heteromodal, binding
convergent input from unimodal areas, thus acting as critical
gateways for information processing and synthesis [45].
Correlations between thickness of the individual regions and
hippocampal volume may reflect underlying patterns of neuropa-
thology. Thickness of the medial portion of the orbital frontal
cortex, inferior temporal gyrus, entorhinal cortex, and the
temporal pole demonstrated the strongest magnitude of associa-
tion with the hippocampus amongst each of the three participant
groups. In contrast, parietal, occipital, and lateral frontal cortices,
correlated with the hippocampus only amongst cognitively normal
older adults and MCI individuals. With AD onset, these regions
failed to associate with the hippocampus. Of interest, these regions
showed the largest magnitude of association with each other
amongst each of the three participant groups (Tables 3, 4 and 5).
One explanation for these findings may involve the evolution of the
neuropathologic cascade in AD. Amyloid deposits are first noted in the
medial portions of the orbital frontal, basal temporal and entorhinal
cortices and tau-associated NFTs initially affect the medial temporal
and temporopolar cortices [1,2]. With disease progression, these
pathologic changes involve the parietal, primary occipital, and lateral
frontal cortices [1–3]. Thus, those neocortical regions that show early
pathologic changes may correlate with each other throughout the
duration of the disease process whereas regions affected later may best
associate with each other rather than earlier involved regions.
Another possibility is that associations between regions reflect
underlying anatomic connections and the decreased correlation
coefficients noted with AD onset represent a selective disruption in
cortico-hippocampal connectivity. Though several studies have
noted disruptions in anatomic connectivity with AD [8,13,46], the
fact that the cognitively normal older adults when compared with
the MCI and AD individuals demonstrated decreased correlation
coefficients between several neocortical regions (including the
entorhinal cortex) and the hippocampus (Table 5) suggests that
the gray matter associations presented here likely do not represent
cortico-hippocampal connectivity. Using diffusion tensor imaging
withanatomiclocalization[47],futureworkwillinvestigatewhether
cortico-hippocampal circuitry is selectively vulnerable in dementia.
Heteromodal cortices, Ab, and p-tau as predictors of
hippocampal atrophy
Significant reductions in CSF Ab levels and elevations in CSF p-
tau levels coupled with thinning within select heteromodal regions
Figure 2. General linear model analyses demonstrating the prediction of longitudinal hippocampal atrophy (over one year) using
baseline cortical thickness for the amyloid positive (top panel) and p-tau positive individuals (bottom panel). All results are corrected
for multiple comparisons by method of Monte Carlo simulation and shown on the gray matter surface (only right hemisphere). The color scale
illustrates the magnitude of effect with blue indicating areas of strongest prediction strength.
doi:10.1371/journal.pone.0012853.g002
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demonstrated a significant relationship between neocortical
amyloid deposition and hippocampal atrophy [48–51]. Our
findings indicate that in addition to amyloid, tau may predict
downstream hippocampal degeneration. Within both the amyloid
and p-tau positive MCI and AD individuals, thickness of the same
two neocortical regions (entorhinal cortex and inferior temporal
gyrus) (Figure 2) significantly predicted hippocampal atrophy
whereas within the amyloid and p-tau negative individuals none of
the neocortical regions predicted hippocampal decline. This
suggests that those neocortical regions that are likely affected by
both Ab and tau influence hippocampal degeneration.
Disruption of select heteromodal regions amongst
asymptomatic older individuals – evidence for a
‘preclinical’ phase of dementia
Amongst cognitively normal older adults, cortical thinning of
the medial orbital frontal cortex significantly differentiated
amyloid positive from amyloid negative individuals whereas
thinning of the entorhinal cortex significantly discriminated p-
tau positive from p-tau negative individuals. Consistent with
neuropathology studies, which demonstrate early amyloid depo-
sition within the medial orbital frontal cortex and early NFT
accumulation within the entorhinal cortex [1,2], our results
indicate that Ab and tau pathology differentially affect neocortical
regions even among asymptomatic older individuals. To our
knowledge, this is the first in vivo evidence that amongst cognitively
normal individuals tau pathology selectively affects the thickness of
the entorhinal cortex. It is important to note that almost half (47%)
of the p-tau positive individuals were additionally amyloid positive
and future work will involve looking at the interaction between Ab
and tau pathology.
The finding that amyloid positive individuals show selective
thinning within the medial orbital frontal cortex is in agreement
with one prior study demonstrating that older individuals with
subjective memory complaints show significant correlations
between gray matter atrophy and neocortical PiB increase within
the medial orbital frontal/anterior cingulate cortex [52]. Addi-
tionally, this is compatible with functional connectivity studies
illustrating that amyloid deposition amongst older individuals
disrupts the ‘default network’, which includes the medial aspect of
the prefrontal cortex [14,53]. Consistent with prior work [54,55],
our results indicate that amongst asymptomatic older individuals
APOE e4 carrier status influences CSF Ab levels but does not
affect CSF p-tau levels. Taken together, this indicates that a
number of cognitively normal individuals harbor preclinical
Figure 3. Bar plots illustrating mean cortical thickness, standardized to Z scores, for the 8 neocortical ROIs amongst the amyloid
positive (Ab+), amyloid negative (Ab2), p-tau positive (Pt+), and p-tau negative (Pt2) older individuals. Error bars indicate 1 standard
error of the mean.
doi:10.1371/journal.pone.0012853.g003
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represent the biological phenotype of the APOE e4 genotype.
Clinical Implications and Further Observations
These findings have important clinical implications. Subtle gray
matter disturbances in specific regions of the cerebral neocortex
are present amongst a subset of asymptomatic older individuals
and can be quantified using sensitive structural neuroimaging
techniques. In combination with CSF Ab and tau, structural MRI
measures can provide an indication of disease stage and have value
in identifying those who will likely benefit from early therapeutic
interventions. Our results also indicate the importance of
administering anti-amyloid therapy early in the disease process
(at a pre-MCI stage) in order to alter or delay hippocampal
degeneration and thus progressive memory loss, the harbinger of
clinical Alzheimer’s dementia.
Why does neurodegeneration affect select cerebral cortical
regions? From a phylogenetic perspective, heteromodal and
archicortical medial temporal regions constitute the oldest areas
of the brain [56], operating as connectional gateways for
information synthesis [44,45], and as such, are likely subject to
greater evolutionary selection pressure for degeneration than
‘newer’ brain regions such as the primary sensory areas. Another
possibility is that those parts of the brain that need to sustain the
highest level of plasticity are most susceptible to degeneration [57].
It is important to note that these two hypotheses need not be
considered mutually exclusive. That is, the oldest and densely
connected brain regions also presumably have the highest
neuroplasticity demands and as such, may be particularly
vulnerable to neuropathologic changes.
Limitations and Caveats
This study has several limitations. One issue involves the use of
gyral-based neuroanatomic ROIs to examine specific neocortical
regions. It is likely the case that Alzheimer’s pathology does not
follow the specific boundaries of these ROIs and affects areas
within and across multiple ROIs. The use of regions of interest
generated from a disease specific effect [19,20] presents one
approach to overcome this limitation. However, as discussed in
[58], this method can underestimate or miss disease specific effects
potentially leading to false negative findings. Future work will
involve combining a priori anatomically defined regions with
disease-based statistical methods to examine neocortical and
subcortical areas in AD. Another limitation involves the use of
CSF Ab and p-tau to assess the presence of amyloid and
neurofibrillary pathology in the neocortex. Though amyloid load
as measured using PiB and CSF Ab are highly correlated and
likely reflect plaque deposition [59], assessments using PiB may
provide a more direct estimate of neocortical amyloid. Similarly,
though prior work indicates that CSF p-tau and cortical NFTs are
significantly correlated in AD [29], measurements using PET
imaging agents that target tangle deposits [60] may offer a more
exact estimate of neocortical neurofibrillary pathology.
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